{"id":"18f-v-6-bp","_chembl":{"chemblId":"CHEMBL1401324","moleculeType":"Small molecule","molecularWeight":"340.42"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"αvβ6 integrin","explanation":"18F-αvβ6-BP is a radiolabeled peptide that selectively binds to the αvβ6 integrin receptor. This integrin is upregulated in multiple cancers and fibrotic conditions, making it a valuable biomarker for disease detection and monitoring through PET imaging.","oneSentence":"A fluorine-18 labeled radiotracer that binds to αvβ6 integrin for PET imaging of cancer and fibrotic diseases."},"_scrapedAt":"2026-03-28T06:50:43.939Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123347,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"18F-FDG","brand":null,"company":null,"rationale":"Standard PET radiotracer for cancer imaging"},{"name":"68Ga-DOTA-TOC","brand":null,"company":null,"rationale":"PET radiotracer for tumor receptor imaging"}],"description":"18F-αvβ6-BP is an investigational radiotracer in Phase 1 development for molecular imaging. It is designed to bind to the αvβ6 integrin, a protein overexpressed in various cancers and fibrotic diseases, enabling visualization through positron emission tomography (PET) scanning.","indications":{"approved":[{"status":"investigational","condition":"Cancer imaging","patientPopulation":"Adult patients requiring tumor visualization"},{"status":"investigational","condition":"Fibrotic disease imaging","patientPopulation":"Adult patients with suspected fibrosis"}]},"trialDetails":[{"nctId":"NCT04376593","phase":"EARLY_PHASE1","title":"PET/CT Imaging in COVID-19 Patients","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2020-05-01","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":5},{"nctId":"NCT05452005","phase":"PHASE1","title":"Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2022-09-13","conditions":"Lung Cancer, Lung Cancer Metastatic, Brain Metastases","enrollment":20},{"nctId":"NCT03164486","phase":"EARLY_PHASE1","title":"First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Julie L. Sutcliffe, Ph.D","startDate":"2016-11","conditions":"Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Image Enhancement Agent"],"phase":"phase_1","status":"active","brandName":"18F-αvβ6-BP","genericName":"18F-αvβ6-BP","companyName":"Julie L. Sutcliffe, Ph.D","companyId":"julie-l-sutcliffe-ph-d","firstApprovalDate":"","aiSummary":"18F-αvβ6-BP is a small molecule used in clinical trials for various types of cancer, including breast carcinoma, colorectal carcinoma, and lung carcinoma. It is being studied as a potential intervention for metastatic malignant neoplasms in the breast and colon.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}